Clinical Trials Search

As a clinical trial candidate at Methodist, you’re offered unique access to new drugs and technology being studied to improve patient outcomes.
Filter by Disease or Condition
Showing 1-10 results of 10
Gynecologic Cancer

GOG FOUNDATION- GOG-3103/Trofuse-022 MK-2870-022

Official Title: A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer
Study Purpose: To test the safety, efficacy, and effect on quality of life of sac-TMT when given alone, with bevacizumab, or compared to no maintenance treatment.
Status: Suspended
Gynecologic Cancer

Gradalis / CL-PTL-135

Official Title: Blood and Tissue Procurement Protocol for Product Development and Research
Study Purpose: To collect cancerous tissue/fluid and blood samples to store and use for research purposes.
Status: Suspended
Gynecologic Cancer

INCB123667-203 Incyte/GOG-3129

Official Title: A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 1)
Study Purpose: To understand how well INCB123667 works, how safe it is, and how well it is tolerated in people with platinum-resistant ovarian cancer whose tumors have high levels of cyclin E1.
Status: Recruiting
Gynecologic Cancer

NRG / CC008

Official Title: A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
Study Purpose: The purpose of the study is to compare two surgical procedures and their ability to decrease the risk of developing ovarian cancer for pre-menopausal women with BRCA1 mutations.
Status: Recruiting
Gynecologic Cancer

NRG / GY024

Official Title: Groningen International Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) III: A Prospective Phase II Treatment Trial  
Study Purpose: To investigate the safety of replacing inguinofemoral lymphadenectomy by chemoradiation in early stage vulvar cancer patients with a macrometastasis and/or extracapsular extension in the SN.
Status: Recruiting
Gynecologic Cancer

NRG / GY026

Official Title: Testing the addition of Herceptin Hylecta or Phesgo to the usual chemotherapy for HER2 positive endometrial serous carcinoma or carcinosarcoma.
Study Purpose: To determine if the addition of the study drugs will lower the chance of this disease from coming back.
Status: Recruiting
Gynecologic Cancer

NRG GY025

Official Title: A Randomized Phase II Trial of Nivolumab and Ipilimumab compared to Nivolumab Monotherapy in patients with deficient mismatch repair system recurrent endometrial carcinoma.
Study Purpose: To find out if combining two immunotherapy drugs, nivolumab and ipilimumab, is better or worse than the usual approach with a single immunotherapy agent.
Status: Recruiting
Gynecologic Cancer

NRG-GY032

Official Title: A Phase II Study of Tailored Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endormetrial Cancer (RAINBO BLUE & TAPER)
Study Purpose: To determine if there are types of early-stage endometrial cancer that require less post-surgical treatment than the usual approach.
Status: Recruiting
Gynecologic Cancer

NRG-GY036

Official Title: A PHASE III TRIAL OF ONE VS. TWO YEARS OF MAINTENANCE OLAPARIB, WITH OR WITHOUT BEVACIZUMAB, IN PATIENTS WITH BRCA1/2 MUTATED OR HOMOLOGOUS RECOMBINATION DEFICIENT (HRD+) OVARIAN CANCER FOLLOWING RESPONSE TO FIRST LINE PLATINUM-BASED CHEMOTHERAPY
Study Purpose: To study if the use of Olaparib for one year keeps your ovarian cancer from growing or returning as well as the usual approach of two years.
Status: Recruiting
Gynecologic Cancer

NRG-GY037

Official Title: A Phase III study of induction pembrolizumab and chemotherapy followed by pembrolizumab before chemoradiation and pembrolizumab maintenance compared to standard chemoradiation with pembrolizumab followed by pembrolizumab maintenance in high-risk cervical cancer
Study Purpose: To find out if adding an immunotherapy drug plus chemotherapy before starting the usual combination of chemotherapy and radiation will increase overall survival or improve recurrence-free survival from cervical cancer.
Status: Recruiting